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Abstract
Background: This study was to evaluate the effect of excision repair cross-complementation group 1(ERCC1)
expression on response to cisplatin-based induction chemotherapy (IC) followed by concurrent chemoradiation
(CCRT) in locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) patients.
Methods: Fifty-seven patients with locally advanced unresectable HNSCC who received cisplatin-based IC followed
by CCRT from January 1, 2006 through January 1, 2008. Eligibility criteria included presence of biopsy-proven
HNSCC without a prior history of chemotherapy or radiotherapy. Immunohistochemistry was used to assess ERCC1
expression in pretreatment biopsy specimens from paraffin blocks. Clinical parameters, including smoking, alcohol
consumption and betel nuts chewing, were obtained from the medical records.
Results: The 12-month progression-free survival (PFS) and 2-year overall survival (OS) rates of fifty-seven patients
were 61.1% and 61.0%, respectively. Among these patients, thirty-one patients had low ERCC1 expression and
forty-one patients responded to IC followed by CCRT. Univariate analyses showed that patients with low expression
of ERCC1 had a significantly higher 12-month PFS rates (73.3% vs. 42.3%, p < 0.001) and 2-year OS (74.2 vs. 44.4%,
p = 0.023) rates. Multivariate analysis showed that for patients who did not chew betel nuts and had low
expression of ERCC1 were independent predictors for prolonged survival.
Conclusions: Our study suggest that a high expression of ERCC1 predict a poor response and survival to cisplatin-
based IC followed by CCRT in patients with locally advanced unresectable HNSCC in betel nut chewing area.
Background
Squamous cell carcinoma of the head and neck
(HNSCC) is the sixth most common cancer in the
world [1] and two-thirds of these patients initially pre-
sent with locally advanced disease [2]. In Taiwan,
HNSCC rates 4th in male cancer-related deaths [3]
among middle-aged male patients between 25 and 45
years old [4]. Most HNSCC patients in Taiwan diag-
nosed with advanced disease are young men. The main
risk factors of this unique patient population are the
habitual consumption of cigarettes, alcohol, and betel
nuts [5,6].
Although patients with locally advanced HNSCC receive
surgery and radiotherapy, less than 30% will be cured, and
locoregional recurrences or distant metastases develop in
40% to 60% patients [7,8], which occurs with a median
survival rate of no more than 6 months [9]. Some studies
have demonstrated improved locoregional control and
overall survival by adding chemotherapy to radiotherapy
concurrently [10]. The Meta-Analysis of Chemotherapy in
Head and Neck Cancer (MACH-NC) study showed that
concomitant chemoradiation is superior to RT alone for
patients with advanced HNSCC and chemoradiotherapy
(radiotherapy plus concurrent chemotherapy) has become
the standard of care for patients with unresectable
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HNSCC [11,12]. However, the best chemotherapeutic regi-
men combined with RT in HNSCC has yet to be defined;
the concomitant administration of cisplatin represents a
widely accepted choice. It has been reported that induc-
tion chemotherapy (IC) with cisplatin and fluorouracil
(PF) benefits this disease [12-14] and results in a signifi-
cantly improved 5-year survival rate in patients with
locally advanced disease compared to surgery and stan-
dard radiotherapy alone [12].
In Taiwan, for public healthy insurance, cisplatin is the
backbone of the chemotherapy regimen as a component
of IC and CCRT in the treatment of locally advanced
HNSCC. Its main cytotoxic activity is based on the for-
mation of DNA adducts, which cause inter- and intras-
trand cross-linking. These DNA cross-links are
recognized and removed by the nucleotide excision repair
pathway which arms to guard the integrity of the genome
[15,16]. The enzyme excision repair cross-complementa-
tion group 1(ERCC1) plays a rate limiting role in the
nucleotide excision repair pathway, and its expression
has been associated with survival in patients with various
malignancies [17-19]. The relation between ERCC1
expression and resistance to platinum compounds had
been found by some clinical studies in patients with
advanced-stage gastric, ovarian, colorectal, esophageal,
and non-small-cell lung cancers [15,17,19-21]. However,
there are only few studies to elucidate the relationship
between ERCC1 expression and prognosis in patients
with locally advanced HNSCC treated with CCRT. The
purpose of this study was to evaluate whether the immu-
nohistochemical expression status of ERCC1 can predict
the treatment response and survival in patients with
unresectable HNSCC being treated with cisplatin-based
IC followed by CCRT.
Methods
Patients and treatment
A total of 57 patients with pathologically proven locally
advanced inoperable HNSCC were treated with IC fol-
lowed by CCRT between January 1, 2006 and January 1,
2008 at Kaohsiung Chang-Gung Medical Center (Tai-
wan). To be included, all the patients had to have a
biopsy-proven previously untreated IV (M0) unresectable
squamous cell carcinoma of the head and neck region,
have no synchronous primary tumors, and be ≥18 years
old. In addition, the patients had to have a performance
status (PS) of ≤2 on the Eastern Cooperative Oncology
Group (ECOG) scale, adequate bone marrow, hepatic
and renal function (creatinine clearance >60 ml/min),
and a computed tomography or magnetic resonance
image scan of the head and neck region within three
weeks prior to the initiation of treatment. The clinico-
pathological information including age, gender, tumor
(T) stage, nodal (N) status, TNM stage, and survival was
obtained from the clinical records. The histories of betel
nuts chewing, alcohol and tobacco use were obtained by
our detailed questioning at the patients’ first visit to the
otolaryngology clinic of the hospital.
The IC consisted of 2 cycles of cisplatin 75 mg/m2
and fluorouracil (5-FU) (1000 mg/m2) given as a contin-
uous 24-h infusion for four days. The two cycles of IC
were administered every four weeks. After IC, all
patients received CCRT. During the CCRT, cisplatin
was administered weekly at a dose of 40 mg/m2. RT
was delivered 3-4 weeks after the completion of the IC
with a linear accelerator. Ondansentron ± dexametha-
sone was used as antiemetic treatment. The response to
IC followed by CCRT was assessed according to the
World Health Organization (WHO) criteria. Surgery
was performed six to twelve weeks after completion of
IC followed by CCRT regimen for patients who had
residual disease. Surgery was also allowed for patients
who did not complete chemoradiation and had resect-
able residual disease at the primary site or in the neck.
Patients were evaluated by CT scan or MRI of the head
and neck every three months. Informed consent was
obtained from study participants and protocol for this
study was approved by the Institutional Review Boards
of Chang-Gung Medical Center (Taiwan).
Immunohistochemical staining for ERCC1
Adjacent non-cancerous and tumor HNSCC tissue sam-
ples were selected by a pathologist based on diagnosis
and microscopic morphology. Adjacent non-cancerous
tissue and tumor tissues were fixed with 10% buffered
formalin embedded in paraffin and decalcified in 10%
EDTA solution. Representative blocks of the formalin-
fixed, paraffin-embedded tissues were cut to 4 mm and
deparaffinized with xylene and rehydrated in a series of
ethanol washes (100, 90, 80, and 70%). Slides were
washed with phosphate-buffered saline (PBS) and trea-
ted with 3% H2O2 for 30 minutes to block endogenous
peroxidase activity. Next, the sections were microwaved
in 10 mM citrate buffer, pH 6.0, to unmask the epitopes.
After antigen retrieval, the sections were incubated with
diluted anti-ERCC1 antibody (monoclonal; 8F1; Thermo
scientific, Fremont, CA, USA; 1:100), for 3 h followed by
washing with PBS. Horseradish peroxidase/Fab polymer
conjugate (PicTure™-Plus kit; Zymed, South San Fran-
cisco, CA, USA) was then applied to the sections for 30
min followed by washing with PBS. Finally, the sections
were incubated with diaminobenzidine for 5 min to
develop the signals. A negative control was run simulta-
neously by omitting the primary antibody.
Evaluation of ERCC1 expression
Two pathologists, who were unaware of the clinical data,
evaluated the ERCC1 staining independently under a
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light microscope at a magnification of × 400. The
pathologists recorded whether tumor or stromal cells
expressed ERCC1. The staining intensity was graded on
a scale of 0-3, using adjacent nonmalignant cells as a
reference (intensity 2). Five images of representative
areas were acquired for each specimen. The percentage
of positive nuclei was calculated for each specimen, and
a proportion score was assigned (0 if 0%, 0.1 if 1-9%, 0.5
if 10-49%, and 1.0 if ≧ 50%). The proportion score was
multiplied by the staining intensity to obtain a final
semi-quantitative H score. The median value of the H
score was chosen as the cutoff point for separating low
and high levels of ERCC1 expression [22].
Statistical analysis
Statistical analyses of 2 × 2 tables of categorical variables
were performed using Pearson’s x2 test or Fisher’s exact
test, where appropriate. Survival probability analyses were
performed using the Kaplan-Meier method. Survival was
calculated from the date of start of chemotherapy to the
date of death or most recent follow-up. Progression free
survival (PFS) was defined as the time from the date of
first chemotherapy to the date of first observation of dis-
ease progression, or relapse, or death due to any cause.
Significance between group differences was assessed by
the log-rank test. Multivariate analyses were performed
using a logistic regression model for response and Cox
regression models for PFS and overall survival (OS). Fac-
tors with p-values < 0.05 in univariate analyses were exam-
ined with multivariate regression models. All statistical
tests were two-sided, with significance defined as p < 0.05.
Analyses were performed using SPSS version 13.
Result
Patient characteristics
The median age of the patients was 53 years (range 36-
72 years), and fifty-five (96.5%) out of 57 were men. Ten
patients had IVA and 47 had stage IVB disease. The
most common sites were the oral cavity (24/57, 42.1%),
followed by the oropharynx (21/57, 36.8%) (Table 1).
The median radiation they received was 6600 cGy.
Nineteen patients received more than 70 Gy of radiation
Table 1 Correlation between expression of ERCC1 and clinicopathological factors of HNSCC
ERCC1 P Multivariates analysis P
No. of patients Low expression High expression OR (95% CI)
Age
≦50 22 (38.6%) 11 (50.0%) 11 (50.0%) 0.598 1
> 50 35 (61.4%) 20 (57.1%) 15 (42.9%) 0.47 (0.11, 2.11) 0315
Gender
Male 55 (96.5%) 30 (54.5%) 25 (45.5%) 1.000 1
Female 2 (3.5%) 1 (50%) 1 (50%) 48.36 (0.54, 4313.32) 0.090
Tumor Site
oral cavity 24 (42.1%) 11 (45.8%) 13 (54.2%) 0.057 1
oropharynx 21 (36.8%) 10 (47.6%) 11 (52.4%) 1.58 (0.35, 7.07) 0.549
hypopharynx/Larynx 12 (21.1%) 10 (83.3%) 2 (16.7%) 0.096 (0.007, 1.33) 0.081
Stage
IVa 10 (17.5%) 7 (70.0%) 3 (30.0%) 0.319 1
IVb 47(82.5%) 24 (51.1%) 23 (48.9%) 3.33 (0.39, 27.89) 0.276
T stage
1/2 6 (10.5%) 6 (100%) 0 (0%) 0.027* 1
3/4 51 (89.5%) 25 (49.0%) 26 (51.0%) Indeterminate 0.999
N stage
negative 12 (21.1%) 5 (41.7%) 7 (58.3%) 0.503 1
positive 45 (78.9%) 26 (57.8%) 19 (42.2%) 0.75 (0.15, 3.64) 0.727
Alcohol drinking
Never 11 (17.2%) 4 (36.4%) 7 (63.6%) 0.318 1
Yes 46 (82.8%) 27 (58.7%) 19 (41.3%) 2.49 (0.31, 19.88) 0.388
Smoking
Never 9 (15.8%) 3 (33.3%) 6 (66.7%) 0.275 1
Yes 48 (84.2%) 28 (58.3%) 20 (41.7%) 1.77 (010, 30.72) 0.695
Betel nuts
Never 20 (35.1%) 8 (40.0%) 12 (60.0%) 0.109 1
Yes 37 (64.9%) 23 (62.2%) 14 (37.8%) 12.78 (1.28-127.62) 0.030*
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dose. All patients had received their IC and 53 patients
completed the followed up CCRT.
Clinico-pathologic factors of HNSCC patients with ERCC1
expression
To investigate whether the increased expression of ERCC1
was associated with various prognostic factors, such as
age, gender, and TNM pathologic classification, we classi-
fied the patients into two groups based on their immuno-
histochemical results (low vs. high ERCC1 expression)
(Figure 1A and 1B). The median H score for HNSCC was
1.5. Twenty-six (46%) tumors had an H score of more
than 1.5 and were thus defined as having a high expression
of ERCC1. As can be seen in Table 1 a summary of result
of the ERCC1 immunostaining of the cancer cells and its
correlation with the clinicopathologic variables, the high
and low ERCC1 expression groups did not significantly
with regard to age, gender, TNM tumor stage, and node
metastatic status, alcohol drinking or smoking (Table 1).
The high ERCC1 expression group had a higher T stage
(T3-4) (p = 0.027). Those with squamous cell carcinoma
of the hypopharynx/larynx were found to have marginal
lower expression of ERCC1. Interestingly, in our multivari-
ate regression model, patients who habitually chewed betel
nuts had a significantly higher expression of ERCC1.
Relationship between treatment response and ERCC1
expression
The overall response rate after CCRT for all patients
was 72% (41/57 with 28 complete responses and 13 par-
tial responses; 9 had stable disease and 7 progressive
disease). Patients with low expression of ERCC1 had a
higher treatment response (28/31, 90.3%) than the high
expression group (13/26, 50%) (p = 0.002, Table 2).
Relationship between survival and ERCC1 expression
The median follow-up was 24.0 months (6 - 46 months).
The overall 12-month PFS rate was 61.1% and the 2-
year OS rate was 61.0%. The 12-month PFS for patients
with low expression of ERCC1 was 73.3% compared
with 42.3% for patients with high expression of ERCC1
(p < 0.001, Figure 2A). The 2-year OS rate was signifi-
cantly higher in patients with low expression of ERCC1
(74.2%) than in those with high expression of ERCC1
(44.4%) (P = 0.023, Figure 2B). Univariate analysis
showed that tumor stage and tumor location were
important factors affecting the OS and PFS (Table 3),
though ERCC1 expression and betel nuts chewing were
the prognostic factors in OS by multivariate analysis
according to Cox regression model (Table 4).
Discussion
It is of special interest that in our study that specimens
from patients who habitually chewed betel nuts had
high expression of ERCC1. Betel nut chewing is a com-
mon habit among those who live in South Asia, includ-
ing Taiwan [23], and is known as one cause of HNSCC
[24]. There are many compounds in the betel nut that
have been correlated with carcinogenesis; the habit of
chewing betel nut is related to persistent damage of the
oral mucosa as well as precancerous lesions such as leu-
koplakia and erythroplakia, and oral submucosal fibrosis
[25]. In previous reports, overexpression of epidermal
growth factor receptor (EGFR) was found to be involved
in betel nut-related HNSCC [26,27]. However, the rela-
tionship between betel nut and ERCC1 expression has
not been reported before. In this study, we find tissue
samples from patients with habitual consumption of
betel nuts showed significant correlation with high
ERCC1 expression. This finding awaits confirmation by
prospective studies with large numbers of patients.
In this study, Forty-six percent of the patients with
inoperable HNSCC had a high expression of ERCC1.
Patients with a high expression of ERCC1 had a lower
treatment response rate to IC followed by CCRT than
those with low expression of ERCC1. In addition, low
Figure 1 Analysis of ERCC1 expression in head and neck squamous cell carcinoma. ERCC1 expression was determined using
immunohistochemistry. A) Low ERCC1 expression (200× magnification). B) High ERCC1 expression (200× magnification).
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Figure 2 Kaplan-Meier estimates of the probability of survival. (A) PFS according to ERCC1 expression. PFS: progression free survival. (B) OS
according to ERCC1 expression. OS: overall survival.
Table 2 Relationship between treatment response and clinicopathological factors
Treatment response Multi-variates




≦50 15 (68.2%) 7 (31.8%) 0.844 1
> 50 26 (74.3%) 9 (25.7%) 0.53 (0.07, 3.65) 0.520
Gender
male 39 (70.9%) 16 (29.1%) 1.000 1
female 2 (100%) 0 (0%) Indeterminate 1.000
Tumor Site
oral cavity 15 (62.5%) 9 (37.5%) 0.049* 1
oropharynx 14 (66.7%) 7 (33.3%) 1.29 (0.21, 7.70) 0.778
hypopharynx/larynx 12 (100%) 0 Indeterminate 0.998
Stage
IVa 10 (100%) 0 (0%) 0.048* 1
IVb 31 (66.0%) 16 (34.0%) Indeterminate 0.998
T stage
1/2 6 (100%) 0 (0%) 0.170 1
3/4 35 (68.6%) 16 (31.4%) Indeterminate 0.999
N stage
negative 8 (66.7%) 4 (25.0%) 0.732 1
positive 33 (73.3%) 12 (26.7%) 0.75 (0.06, 8.54) 0.818
Radiation
≦6000 cGy 14 (70.0%) 6 (30.0%) 1.000 1
> 6000 cGy 27 (75.7%) 10 (24.3%) 0.22 (0.02, 2.43) 0.222
Alcohol drinking
never 9 (81.8%) 2 (18.2%) 0.710 1 0.120
yes 32 (69.6%) 14 (30.4%) 0.08 (0.004, 1.89)
Smoking
never 7 (77.8%) 2 (22.2%) 1.000 1
yes 34 (70.8%) 14 (29.2%) 2.97 (0.10, 86.59) 0.526
Betel nuts
never 16 (80.0%) 4 (20.0%) 0.491 1
yes 25 (67.6%) 12 (32.4%) 0.38 (0.03, 4.55) 0.452
ERCC1
low expression 28 (90.3%) 3 (9.7%) 0.002* 1
high expression 13 (20.0%) 13 (50.0%) 0.07 (0.009, 055). 0.012*
CR, complete response; PR, partial response; SD, stable disease; PD, disease progression; RTO, radiotherapy; OR, odds ratio; CI, confidence interval.
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ERCC1 expression was associated with a significantly
longer PFS and OS. Multivariate analysis revealed that
low expression of ERCC1 to be an independent factor
associated with a lower risk of cancer death (HR 0.31,
p = 0.010). Our findings are consistent with previous
report of an increase in tumor response and prolonga-
tion of OS in patients treated by cisplatin based IC fol-
lowed by CCRT for locally advanced HNSCC [28-30].
Moreover, the relationship between the expression of
ERCC1 and tumor response or survival has also been
demonstrated in esophageal cancer patients treated
with chemoradiotherapy [31] and non-small cell lung
cancer treated with cisplatin-based adjuvant che-
motherapy [22].
However, in patients with locally advanced HNSCC
treated with cetuximab-based CCRT, ERCC1 expression
has not been found to predict treatment response [32].
In this context, we assume that pre-therapeutic ERCC1
protein levels within tumor cells might be correlated
with their cisplatin-related DNA damage repair capacity.
A less efficient DNA-repair capacity could affect the cel-
lular response to DNA damage and could thus render
cancer cells more sensitive to cisplatin. In addition, Nix
et al. has reported an association between both ERCC1
and XRCC1 and radioresistance in laryngeal tumors
[33].
Cetuximab is an IgG1 monoclonal antibody against
the ligand-binding domain of EGFR. Cetuximab binds
Table 3 Univariate analyses of prognostic factors for survival
Variables No. of
patients
Cumulative 12-month preogresion free survival
rate




< 50 22 49.0% 0.725 50.0% 0.152
≧50 35 68.6% 68.0%
Gender
male 55 61.5% 0.878 65.2% 0.553
female 2 50.0% 50.0%
Site
oral cavity 24 41.7% 45.5% 0.093
oropharynx 21 66.7% 0.101 66.6%
Hypopharynx/
larynx
12 81.8% 0.035* 83.3%
Stage
IVa 10 80.0% 0.119 90.0% 0.049*
IVb 47 57.2% 54.7%
T stage
0-2 6 66.7% 0.396 66.7% 0.694
3-4 51 60.5% 60.3%
N stage
negative 12 50.0% 0.837 72.9% 0.350
positive 45 57.3% 57.8%
Radiation
≦6000 cGy 20 55.0% 0.304 55.0% 0.412
> 6000 cGy 37 64.5% 64.1%
Alcohol
never 11 63.6% 1.000 63.6% 0.754
yes 46 60.6% 64.8%
Smoking
never 9 66.7% 0.614 66.7% 0.679
yes 48 60.1% 60.0%
Betel nuts
never 20 70.0% 0.638 74.0% 0.123
yes 37 56.3% 54.1%
ERCC1
low expression 31 73.7% <
0.001*
74.2% 0.023*
high expression 26 42.3% 44.4%
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EGFR, sequesters the receptor in the cytoplasm and
eventually targets it for degradation. In vitro studies
have demonstrated that this antibody enhances the
radio-sensitivity in HNSCC cells [34,35] through several
processes, such as DNAPK, which are reviewed in
Mukesh et al. [36]. When cetuximab is combined with
radiation, it has been found to inhibit the nuclear trans-
location of the complex between DNA-dependent pro-
tein kinase and EGFR and then delayed the DNA repair
[37-39]. Oxaliplatin induced double-strand breaks [40].
When cetuximab was combined with oxaliplatin, cetuxi-
mab reduced the expression of ERCC-1 and other genes
involved in DNA replication initiation [41,42]. We
might find a subgroup of patients with high ERCC1
expression having poor response to cisplatin-based IC
and CCRT that is particularly benefited from treatments
with cetuximab and other chemotherapeutic agents.
Our study has several limitations. First, the study
was based on a retrospective analysis and only there
were only 57 patients accumulated over a short per-
iod. The primary tumor site was also heterogeneous,
and the prognosis of HNSCC is dependent on the pri-
mary tumor site. In our study, those oral cavity cancer
had the worst prognosis and laryngeal cancer a good
prognosis, although we found no significant difference
in our multi-variate analyses. Second, some patients
with IC followed by CCRT had a partial response and
received further salvage surgery. Patients who receive
salvage surgery had significantly longer PFS and OS
rates than those who did not receive such surgery.
The salvage surgery may affect the relationship
between ERCC1 expression and survival. It also sug-
gested that those patients with lower expression of
ERCC1 would benefit from the potential downstage by
our treatment protocol and become resectable. Our
study was comprised only a small number of patients
for each tumor location, and so we may need more
homogeneous and a larger number of patients to vali-
date this finding.
Conclusion
This present study suggests that ERCC1 mediated repair
of DNA damage contributes to the clinical outcome in
patients with locally advanced inoperable HNSCC trea-
ted with cisplatin-based IC and CCRT. In this context,
it is strongly recommended that tissue be collected to
assess ERCC1 expression before cisplatin-based induc-
tion chemotherapy and concurrent chemoradiotherapy.
If patients with habit of betel nuts chewing may have
higher chance of high ERCC1 expression, they should
consider other treatment approach modalities.
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